Please enter your search term here
Home
·
|
Merck Group
·
|
Contact
·
|
Deutsch
·
|
Sitemap
·
|
Search
Sitemap
Merck 2011 at a glance
Letter from Karl-Ludwig Kley
Executive Board
Key Events in 2011
Business Development 2002-2011
Financial Calendar
Corporate Governance
Statement on Corporate Governance
Merck KGaA
Compensation report
Executive Board
Supervisory Board
Ownership of shares
Corporate Governance Practices
Principles
Values and compliance
Procedures of the corporate bodies
Executive Board
Supervisory Board
Board of Partners of E. Merck KG
Report of the Supervisory Board
Objectives of the Supervisory Board
Merck in the Capital Market
Share price development
Share data
Shareholder
Merck bonds
Group Management Report
Economic Situation
Financial Position and Results of Operations
Business development
Business sectors
Regions
Acquisitions
Total assets
Free cash flow
Capital spending
Key financial performance indicators
Value added
Capital and shares
Corporate Responsibility
Employees
International human resources work
Diversity in the workforce
Products and the environment
Society
Corporate and Other
Risk Report
Business-related risks
Financial risks
Legal risks
Human resources risks
Information technology risks
Environmental and safety risks
Report on Expected Developments
Global economy
Forecast for sales and operating result
Subsequent Events
Merck Serono
Business development
Regions
Therapeutic areas
Oncology
Multiple Sclerosis
Fertility
Endocrinology
CardioMetabolic Care and General Medicine
Research & Development
Overview compounds
Oncology
Multiple sclerosis
Parkinson
Fertility
Endocrinology
Rheumatological diseases
Consumer Health Care
Business development
Brands
Regions
Merck Millipore
Business development
BioScience
Lab Solutions
Process Solutions
Performance Materials
Business development
Liquid Crystals
Pigments & Cosmetics
Financial Statements
Income Statement
Comprehensive Income
Balance Sheet
Cash Flow Statement
Changes in Net Equity
Notes
Scope of consolidation
Accounting policies
Notes to the consolidated income statement
Sales
Royalty, license and commission income
Cost of sales
Marketing and selling expenses
Royalty, license and commission expenses
Administration expenses
Other operating expenses and income
Research and development
Amortization of intangible assets
Investment result
Exceptional items
Financial result
Income tax
Non-controlling interest
Earnings per share
Notes to the consolidated balance sheet
Cash and cash equivalents
Marketable securities and financial assets
Trade accounts receivable
Inventories
Other assets
Tax receivables
Assets held for sale and liabilities directly related to assets held for sale
Intangible assets
Property, plant and equipment
Investments at equity
Non-current financial assets
Financial assets covering pension obligations
Financial liabilities
Trade accounts payable
Other liabilities
Tax liabilities
Provisions
Provisions for pensions and other post-employment benefits
Equity
Segment reporting
Notes to the consolidated cash flow statement
Net cash flows from operating activities
Net cash flows from investing activities
Net cash flows from financing activities
Cash and cash equivalents
Free cash flow and underlying free cash flow
Other disclosures
Derivative financial instruments
Management of financial risks
Other disclosures on financial instruments
Capital management
Contingent liabilities
Other financial obligations
Personnel expenses / Headcount
Material costs
Auditors’ fees
Corporate governance
Companies opting for exemption under section 264 (3) HGB
Related-party disclosures
Executive Board and Supervisory Board compensation
Information on preparation and approval
Subsequent events
List of shareholdings
Auditor’s Report
The road to tomorrow
Innovative
Dynamic
Future-oriented
Values-based
Merck: Fit for 2018
SERVICES
Recommend page
Print page
Order online
Glossary
Downloads
CHART GENERATOR
Important key figures
Home
Merck 2011 at a glance
Corporate Governance
Merck in the Capital Market
Group Management Report
Merck Serono
Consumer Health Care
Merck Millipore
Performance Materials
Financial Statements
Notes
The road to tomorrow
made by Nexxar - your next annual report online!, Vienna - Austria
